HC Wainwright & Co. Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $25

Benzinga Newsdesk www.benzinga.com Neutral 62.8%

Neg 0% Neu 62.8% Pos 0%

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $50 to $25.